Gilead Sciences (NASDAQ:GILD) said it has received FDA Breakthrough Therapy Designation for its antibody-drug conjugate ...
Tolebrutinib, expected to soon be submitted for U.S. approval for nonrelapsing SPMS, was granted the FDA's breakthrough ...
City of Hope scientists have identified a protein, YTHDF2, that helps cancer cells evade CAR T cell therapy. They developed a ...
The FDA granted breakthrough therapy designation to dostarlimab for locally advanced dMMR/MSI-H rectal cancer, highlighting ...
Scientists have discovered a key protein that helps cancer cells avoid detection by the immune system during a type of ...
(RTTNews) - Gilead Sciences, Inc. (GILD) Tuesday said that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adults with ...
Gilead (GILD) announced that the FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adult patients with ...
The Breakthrough Therapy designation is supported by data from the randomized, open-label phase 2 SOLSTICE trial.
5d
Zacks.com on MSNSNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMSSanofi SNY announced that the FDA has granted a Breakthrough Therapy designation to its investigational oral BTK inhibitor, ...
The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum ...
AIIMS researchers claim to have made significant progress in developing chimeric antigen receptor (CAR) T-cell therapy, ...
Monroe Carell was a natural fit to offer the new therapy. Its multidisciplinary DMD Clinic, co-directed by Burnette, Soslow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results